Back to Search
Start Over
Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab
Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab
- Source :
- JACC: Basic to Translational Science
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
-
Abstract
- Visual Abstract<br />Highlights • PON-1 is an HDL-associated cardioprotective enzyme that prevents oxidized-LDL formation and has not previously been studied in cardio-oncology. • To determine the associations between PON-1 and the development of CTRCD, the Pon and Aryl serum enzymatic activity levels of PON-1 were quantified in a cohort of 225 patients with breast cancer receiving doxorubicin with or without trastuzumab. • After doxorubicin completion, the activity levels of both Pon and Aryl were significantly decreased. • Early increases in the Pon enzymatic activity of PON-1 were associated with increased risk of CTRCD. • With further study, PON-1 activity may provide insight into mechanistic risk prediction of CTRCD with doxorubicin chemotherapy.<br />Summary The objective of this study was to determine associations of paraoxonase-1 (PON-1) with development of cancer therapy–related cardiac dysfunction (CTRCD). PON-1 is a cardioprotective enzyme associated with high-density lipoprotein that prevents oxidized low-density lipoprotein formation. Given the role of oxidative stress in doxorubicin-induced cardiotoxicity, PON-1 activity may have relevance for the prediction of CTRCD. In 225 patients with breast cancer receiving doxorubicin with or without trastuzumab, we quantified PON-1 activity through its paraoxonase (Pon) and arylesterase (Aryl) enzymatic activity at baseline, during, and after doxorubicin completion. Echocardiograms were performed at baseline, during therapy, and annually. CTRCD was defined as a decrease in left ventricular ejection fraction by ≥10% from baseline to
- Subjects :
- cardiac dysfunction
BMI, body mass index
CTRCD, cancer therapy–related cardiac dysfunction
HDL, high-density lipoprotein
cardiotoxicity
Aryl, arylesterase
heart failure
CVD, cardiovascular disease
doxorubicin
Clinical Research
LDL, low-density lipoprotein
LVEF, left ventricular ejection fraction
PON-1, paraoxonase-1
HER2, human epidermal growth factor receptor 2
Pon, paraoxonase
Cardiology and Cardiovascular Medicine
paraoxonase-1
Subjects
Details
- ISSN :
- 2452302X
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- JACC: Basic to Translational Science
- Accession number :
- edsair.doi.dedup.....2dadd34a04c67d94c46bd9d5fb98d63f
- Full Text :
- https://doi.org/10.1016/j.jacbts.2021.10.010